ClinicalTrials.gg

Program

vixticibart

Its studies are mostly in Heart Failure · Hypertension, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Apr 25, 20224 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals40 open or runningphase 2since Apr 25, 2022Jul 28, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2020First study: phase 1 study in HealthyFirst studyNCT04506645 · 90 enrolled · Belgium
  2. Apr 25, 2022Phase 2 study in Heart FailureNCT05353166 · 59 enrolled · Moldova
  3. Jan 23, 2024Phase 2 study in Heart FailureNCT06237309 · 89 enrolled · United States, Belgium, Bulgaria and more
  4. Feb 12, 2025Phase 2 study in HypertensionNCT06833190 · 34 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06833190Hypertension · United Kingdom2TerminatedOct 15, 202534
NCT06237309Heart Failure · United States, Belgium, Bulgaria and more2TerminatedSep 17, 202589
NCT05353166Heart Failure · Moldova2CompletedJun 2, 202559
NCT04506645Healthy · Belgium1CompletedDec 14, 202290

How it is read

Names in the registry

  • “REGN5381”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
vixticibart (Regeneron Pharmaceuticals): development program | ClinicalTrials.gg